Torsten Goesch

Partner, Rosetta Capital Limited, Dr. Torsten Goesch has been the director of Rosetta Capital, a secondary life science investor, since 2002, and is responsible for the management of several Rosetta Capital investments. As such, he has served on several biotech company boards, including those of Enobia Ltd, Forward Pharma SA, and Cytochroma Ltd. Dr. Goesch is also the founder and former Managing Director of TRG Invest, a Munich-based consulting business serving companies in the life science sector. Additionally, Dr. Goesch served as the General Manager for the German Speaking Countries at Biogen from 1997-1999, and prior to that served as the Commercial Head of Merck KGaA’s worldwide generics drug business, Merck Generics. He practiced as a doctor of internal medicine at the University Hospital Hamburg-Eppendorf from 1988-1990, focusing on nephrology, immunology, and oncology. Dr. Goesch has a Master of Management from Northwestern University’s J.L. Kellogg Graduate School of Management, as well as an M.D. and Ph.D. from Heinrich Heine University Düsseldorf.